Medication warning for everolimus/Afinital high-risk groups

Everolimus (Everolimus), as a targeted drug, has shown significant efficacy in the treatment of various cancers, but it still needs to be used with caution in certain high-risk groups. In clinical applications, everolimus may cause a range of side effects, especially in patients with poor liver function, compromised immune systems, or other potential complications. Therefore, the use of everolimus must be strictly followed by doctors' instructions, especially for high-risk patient groups.

Everolimus must be used with special caution in patients with hepatic impairment. The drug is mainly metabolized by the liver. If the patient's liver function is damaged, the metabolism of the drug may be affected, thereby increasing the drug's blood concentration and toxic reactions. Therefore, patients with hepatic insufficiency should use everolimus under strict supervision by a physician and adjust the dose if necessary.

In addition, everolimus may suppress the immune system and increase the risk of infection. For patients with immune system problems, especially those who have received organ transplants, they should be particularly vigilant about the occurrence of infection when using everolimus. In these patients, everolimus may cause excessive immunosuppression and increase the risk of complications such as infection, upper respiratory tract infection, and pneumonia.

Everolimus may also have an effect on blood sugar levels, particularly in people with diabetes, possibly causing an increase in blood sugar. Therefore, patients with diabetes should monitor blood glucose levels closely while taking everolimus and adjust their treatment regimen if necessary.

During the use of everolimus, patients also need to undergo regular liver function, blood sugar, blood pressure and other related tests to ensure the safety of the drug. In short, although everolimus has significant effects in the treatment of various cancers (renal cell carcinoma, breast cancer, etc.), it must be used with caution in high-risk groups, and patients should be treated under the guidance of professional doctors.

Reference materials:https://www.drugs.com/everolimus.html